Phio Pharmaceuticals Corp, a US-based biotech firm, is making significant strides in the development of immuno-oncology therapeutics. The company's portfolio includes PH-762, which activates immune cells to recognize and destroy cancer cells through the reduction of the checkpoint protein PD-1, and PH-894, a treatment that silences the epigenetic protein BRD4, which regulates gene expression for use in T and tumor cells. Additionally, Phio Pharmaceuticals Corp is developing PH-804, which targets the immune receptor TIGIT, a suppressive checkpoint protein found on T cells and natural killer cells. Founded in 2011 and previously known as RXi Pharmaceuticals Corporation, the company adopted its current name in November 2018. Its headquarters are located in Marlborough, Massachusetts.